What is the current stock price of Cellectis S.A. (CLLS)?

As of the latest market data, Cellectis S.A. (CLLS) is trading at $3.59. The stock has seen a gain of 2.57% today.

Does Cellectis S.A. (CLLS) pay a dividend?

Based on current data, Cellectis S.A. does not have a confirmed active dividend policy.

What is the market cap of Cellectis S.A.?

The current market capitalization of Cellectis S.A. (CLLS) is approximately unavailable.

CLLS

Cellectis S.A.·Healthcare

3.59

2.571%(+0.09)

Market Closed

3.89

8.357%(+0.30)

After Hours

Last Updated: — ET

52W L: $1.3352W H: $5.48

CLLS NEWS

globenewswire.com

3d ago

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)

seekingalpha.com

Mar 20

Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 19

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the fourth quarter and full year 2025, ending December 31, 2025 and provided a business update.

globenewswire.com

Mar 12

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market.

globenewswire.com

Mar 4

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Sector

Healthcare

Industry

Biotechnology

Employees

216

IPO Date

2015-03-24

Beta

2.71

Websitewww.cellectis.com↗